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those with traumatic injury in a multi-payer US population.
Increasing severity appears to increase the likelihood of develop-
ing a DVT. Further, new interventions that mitigate the develop-
ment of DVT may reduce the economic burden of traumatic
injury among pediatric hospitalizations. Clinicians and other
decision makers should be aware of the relationship between
injury severity and DVT development and resource utilization-
associated outcomes.
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OBJECTIVE: Medications used to control DM2 and hyperten-
sion are common associated with ED problems. This had affected
adherence and therefore the long-term control of Mexican
patients with those diseases, increasing long-term complications
and health care costs. The purpose of the study was to evaluate
the cost-effectiveness of using ED treatments as adjuvant thera-
pies in patients with DM2 and hypertension from an institutional
perspective. METHODS: A cost-effectiveness assessment was
performed employing a ten-years decision tree model. Compara-
tors used in the model were Sildenaﬁl (50 mg/day-100 mg/day);
Taladaﬁl (20 mg/day) and Vardenaﬁl (10 mg/day-20 mg/day).
Effectiveness measure used was the number of hospitalization
avoided related to uncontrolled-patients due to ED causes. The
transition probabilities were obtained from international pub-
lished literature and a local survey, previously validated, related
to ED problems in Mexican patients(n = 146 with DM2; n = 326
with hypertension) at multiple second-level Hospitals within the
Social Security Mexican Institute (IMSS). Resource use data was
obtained from hospital records(n = 1000) and a 3% discount
rate was used. The model was calibrated according to interna-
tional guidelines. Probabilistic sensitivity analyses were per-
formed using bootstrapping techniques. RESULTS: Savings per
patient with DM2 were US$816.70 for sildenaﬁl 50 mg/day;
US$668.30 for sildenaﬁl 100 mg/day; US$711.20 for tadalaﬁl;
US$646.30 for vardenaﬁl 10 mg/day and US$603.50 for vard-
enaﬁl 20 mg/day. Annual mean savings per patient with hyper-
tension resulted in US$1627.00; US$1447.50, US$1520.80,
US$1444.50 and US$1432.20; respectively following the order
above. Patients treated with ED therapies avoided signiﬁcant
number of hospitalizations (complications) in both diseases and
sildenaﬁl 50 mg/day was the therapy which showed the higher
number of hospitalizations avoided(23 for DM2 and 25 for
hypertension). ICER’s showed Sildenaﬁl 50 mg/day as the domi-
nant treatment. The results were robust to probabilistic sensi-
tivity analyses and acceptability curves. CONCLUSION: ED
therapies should be employed in males who show this pro-
blem secondary to DM2 and hypertension. These results could be
used by Mexican decision-makers to generate cost-containment
strategies.
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OBJECTIVE: High blood pressure is common in menopausal
women and some hormone therapies (HT) for menopause may
contribute to increased blood pressure. However, the burden of
illness (BOI) of hypertension in women receiving menopausal HT
is not well-documented in the current literature. This study esti-
mates the prevalence and economic burden of hypertension in
this patient population. METHODS: Patients with at least one
prescription for menopausal HT were selected from the Phar-
Metrics database during the period from July 1, 2003–June 30,
2005. HT patients were divided into those with and without
hypertension. The non-hypertensive cohort was propensity score
matched to the hypertensive cohort, controlling for patient
demographics, overall comorbidities, and type of HT use. The
BOI of hypertension was deﬁned as the difference in average
annual total health care expenditures per person between the
cohorts. RESULTS: The prevalence of menopausal HT use was
9.75% among potentially eligible patients in this commercially-
insured sample. Hypertension was the most common comorbid-
ity, with a prevalence of 34%. HT patients with hypertension
(n = 106,729) had signiﬁcantly higher average annual health
care expenditures compared with matched HT patients without
hypertension ($8,908 versus $5,960; difference of $2,948;
P < 0.001). Less than 1% was due to differences in menopause-
related care between the cohorts; 54% was attributable to
hypertension-related care and 45% to the care of other common
comorbidities, such as lipid disorders. CONCLUSION: Hyper-
tension is the most common comorbidity among commercially-
insured menopausal hormone therapy users in the United States.
The annual incremental BOI of hypertension among HT users is
both substantial and statistically signiﬁcant, averaging $2,948
per patient per year. Given the number of menopausal women
who use HT and the prevalence of hypertension in this cohort,
employers and medical care payers should be interested in ﬁnding
ways to lessen the burden associated with hypertension.
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OBJECTIVE: In Ukraine the State program «Reproductive
health of the nation for the period till 2015», providing reduction
in the quantity of abortions is authorized, using hormonal con-
traception. The aim was to identify the most cost-effective oral
or transdermal contraceptives using a provider perspective.
METHODS: A decision tree was developed to compare the cost-
effectiveness of oral contraceptive 3 mg drospirenone/0.03 mg
ethinylestradiol (D-E) vs. 0.25 mg norgestimate/0.035 mg
ethynilestradiol (NA-E) vs. transdermal contraceptive 6 mg
norelgestromin/0.6 mg ethynilestradiol (transdermal N-E) for
preventing a pregnancy per patient per year. Direct medical
cost were based on average wholesale prices for medicines
(01.10.2007), ans physician, laboratory costs based on tariffs of
Lviv family planning center. Probability data that included com-
pliance and pregnancy rates were extracted from randomized
clinical trials and public resources. A probablistic sensitivity
analysis of free parameters was conducted through a Monte-
Carlo simulation. Key parameters were sampled from beta
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